Skip to main content
. 2023 Mar 12;24(1):2166763. doi: 10.1080/15384047.2023.2166763

Figure 3.

Quantitative analysis of CALR expression on the surface of EC cells after treated with ERAD inhibitors and/or RT.

ERAD inhibitor and RT cause CALR exposure to the cell surface in EC cells. (a and b) Cell surface translocated CALR was measured after 24 hours exposure to increasing doses of EerI or NMS-873 in KYSE70 cells (0–5000 nM). (c) Cell surface translocated CALR was detected after 24 hours exposure to increasing doses of RT (0, 2, 6, 10, and 20 Gy) ± EerI (5000 nM) or NMS-873 (500 nM) in KYSE70 cells. (d and e) Cell surface translocated CALR was measured after 24 hours exposure to increasing doses of EerI or NMS-873 in KYSE140 cells (0–5000 nM). (f) Cell surface translocated CALR was detected after 24 hours exposure to increasing doses of RT (0, 2, 6, 10, and 20 Gy) ± EerI (5000 nM) or NMS-873 (500 nM) in KYSE140 cells. CALR: calreticulin; ERAD: endoplasmic reticulum associated protein degradation; EC: esophageal cancer; RT: radiation therapy. Data are means ± SD (N = 3), n.s, not significant, P > .05; *P ˂ 0.05; **P ˂ 0.01; ***P ˂ 0.001.